• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

ADA: Eli Lilly's stellar tirzepatide weight loss data tee up showdown with Novo...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 06, 2022 at 11:42: PM
via Eli Lilly, just weeks after snaring approval for dual GIP/GLP-1 med Mounjaro in Type 2 diabetes, is trumpeting its case for the nascent blockbuster in weight loss. The data likely portend a clash with Novo Nordisk’s obesity stalwart Wegovy, one group of analysts argues.

article source
 

<



Similar threads

cafead
ADA 2023 – Lilly unveils its triple threat
Replies
0
Views
134
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease
Replies
0
Views
81
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ADA 2023 preview – Lilly’s oral obesity data leave room for Pfizer
Replies
0
Views
161
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ADA: Bayer builds its case for potential kidney disease blockbuster Kerendia
Replies
0
Views
99
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Dexcom’s CEO: FDA’s Nod for G7 Could Come Sometime After ADA
Replies
0
Views
151
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote